Currently, no simple point-of-care blood test exists for use by physicians in the emergency room or hospital to detect the presence and severity of brain trauma. Following a brain injury, a destructive cascade of biological events continues over hours and days that may worsen the patient’s condition. Banyan Biomarkers has discovered two protein biomarkers that rapidly appear in the blood of patients soon after injury and has developed assays to quantify these proteins. Detecting these biomarkers may provide early indications of brain trauma in patients and improve clinical outcomes. Currently, the company is evaluating two proprietary proteins, Banyan GFAPTM and Banyan UCH-L1TM for the detection of TBI in a 2,000 patient clinical trial called the ALERT-TBI Study.